<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to preventing relapse of malaria due to &lt;em&gt;Plasmodium vivax&lt;/em&gt; or &lt;em&gt;Plasmodium ovale&lt;/em&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to preventing relapse of malaria due to <em>Plasmodium vivax</em> or <em>Plasmodium ovale</em></h1>
<div class="graphic"><div class="figure"><div class="ttl">Approach to preventing relapse of malaria due to <em>Plasmodium vivax</em> or <em>Plasmodium ovale</em></div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Available antirelapse (hypnozoiticidal) agents*</td> <td class="subtitle1" rowspan="2">Exclusion criteria</td> <td class="subtitle1" rowspan="2">Antimalarial (blood schizonticidal) regimen</td> <td class="subtitle1" colspan="4">G6PD activity<sup>¶</sup></td> </tr> <tr> <td class="subtitle2">&gt;70%</td> <td class="subtitle2">30-70%</td> <td class="subtitle2">&lt;30%</td> <td class="subtitle2">Unavailable</td> </tr> <tr> <td>Primaquine<sup>Δ</sup></td> <td> <ul> <li>Pregnant</li> <li>Lactating</li> <li>≤6 months of age</li> </ul> </td> <td>Chloroquine or an artemisinin combination regimen</td> <td>Adults and children: 0.5 mg base/kg once daily for 14 days (total dose 7 mg/kg over 14 days)<sup>◊</sup></td> <td>Adults and children: 0.5 mg base/kg once daily for 14 days (total dose 7 mg/kg over 14 days)<sup>◊</sup></td> <td>Adults and children: 0.75 mg base/kg once weekly for 8 weeks (total dose 6 mg/kg over 8 weeks)<sup>§</sup></td> <td>Adults and children: 0.25 mg base/kg once daily for 14 days (total dose 3.5 mg/kg over 14 days)<sup>¥</sup></td> </tr> <tr> <td>Tafenoquine</td> <td> <ul> <li>Pregnant</li> <li>Lactating</li> <li>≤2 years of age</li> </ul> </td> <td>Chloroquine</td> <td> <p>Adults and children &gt;35 kg<sup>‡</sup>: 300 mg single dose on day 1 or day 2 of chloroquine</p> <p class="extra_spacing_top">Children ≤35 kg and aged &gt;2 years<sup>‡</sup>:</p> <ul class="decimal_heading"> <li>&gt;10 kg to 20 kg: 100 mg (two 50 mg dispersible tablets)</li> <li>&gt;20 to ≤35 kg: 200 mg (four 50 mg dispersible tablets)</li> </ul> </td> <td>Not recommended</td> <td>Not recommended</td> <td>Not recommended</td> </tr> </tbody></table></div><div class="graphic_lgnd">Hypnozoitocidal therapy for preventing relapse of malaria due to <em>P. vivax</em> and <em>P. ovale</em> is administered in combination with appropriate (primary) blood schizonticidal therapy; refer to UpToDate content on nonfalciparum malaria and separately available tables.</div><div class="graphic_footnotes"><p>G6PD: glucose-6-phosphate dehydrogenase.</p>
<p>* Patients treated with primaquine or tafenoquine should be counseled to report signs of drug-induced hemolysis (dark urine, fatigue, or shortness of breath); in such cases, the drug should be discontinued.</p>
<p>¶ For "normal" G6PD result using a qualitative assay, primaquine is dosed for ≥30% G6PD activity. Use of tafenoquine requires a quantitative G6PD activity assay and a result &gt;70%.</p>
<p>Δ The gastrointestinal tolerability of primaquine can be improved by administering with food.</p>
<p>◊ Doses of primaquine in patients ≥70 kg should be adjusted to a total dose of 7 mg/kg divided into doses of 30 mg per day. The duration of treatment is extended beyond 14 days to achieve total cumulative dose of 7 mg/kg without exceeding the maximum of 30 mg per day. The primaquine dosing regimen differs from 2022 World Health Organization (WHO) guidance; refer to topic on nonfalciparum malaria, section on rationale for use of high-dose primaquine.<sup>[1,2]</sup></p>
<p>§ Patients should be evaluated on day 7 to evaluate for adverse effects.</p>
<p>¥ This regimen is sufficient for preventing most <em>P. ovale</em> relapses and is efficacious for prevention of <em>P. vivax</em> relapse for infection acquired in temperate areas and areas of lower relapse periodicity. Patients should be monitored for hemolysis. Refer to the UpToDate topic on nonfalciparum malaria for further discussion.</p>
‡ Pediatric tafenoquine formulation and dosing in children and adolescents aged &gt;2 through 15 years is licensed in Australia but not in the United States.<sup>[3]</sup></div><div class="graphic_reference">References:
<ol>
<li>Chamma-Siqueira NN, Negreiros SC, Ballard SB, et al. Higher-dose primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 2022; 386:1244.</li>
<li>World Health Organization (WHO). Guidelines for Malaria. Geneva, Switzerland: World Health Organization; June 3, 2022.</li>
<li>Kozenis (tafenoquine) Australian Product Information (revision March 2022) available at http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&amp;id=CP-2018-PI-02316-1 (Accessed on July 19, 2023).</li>
</ol></div><div id="graphicVersion">Graphic 130538 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
